Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arm Holdings plc (ARM) vs Novavax Inc (NVAX) Price & Performance

Arm Holdings plcTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Arm Holdings plc vs Novavax Inc — how do they compare? Arm Holdings plc trades at $274.32 (market cap $286.06B), while Novavax Inc trades at $7.97 (market cap $1.30B). The key difference: Arm Holdings plc is far larger — about 220× Novavax Inc's market cap, and Arm Holdings plc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

ARMNVAX
Market Cap
$286.06B$1.30B
Sector
TechnologyHealth
52-Week High
$439.46$11.19
52-Week Low
$104.55$6.22
Enterprise Value
$282.64B$879.40M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arm Holdings plc

ARM stock trades at $282.57, down 1.43% over 24 hours, with a bullish technical outlook supported by moving averages and key support at $272. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 beating the $0.40 estimate. Revenue grew to $4.01B in 2025, with a net income margin of 20.25%, though valuation multiples remain elevated with a P/E of 273.32.

The outlook is positive due to AI-driven growth in licensing and royalties, with management targeting $25B revenue by FY31. However, risks include stretched valuation, smartphone market headwinds, and execution challenges. Analyst consensus is bullish with a $329.80 price target, suggesting 17% upside from current levels.

Novavax Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Arm Holdings plc

Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.

Read more on ARM

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX